Intermede Investment Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$118M |
| 2 |
Meta Platforms (Facebook)
META
|
+$4.71M |
| 3 |
SLB Ltd
SLB
|
+$2.77M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$83.9M |
| 2 |
Amazon
AMZN
|
+$80.1M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$75.9M |
| 4 |
West Pharmaceutical
WST
|
+$74.8M |
| 5 |
Accenture
ACN
|
+$72.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.78% |
| 2 | Financials | 17.3% |
| 3 | Communication Services | 12.91% |
| 4 | Consumer Discretionary | 11.4% |
| 5 | Industrials | 9.67% |
Similar funds
Intermede Investment Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Intermede Investment Partners held 34 positions worth $3.75B, down 22% from $4.79B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Intermede Investment Partners withdrew a net $1.06B in Q4 2024, closing 1 position and reducing 30 holdings. Its most notable exit was West Pharmaceutical, an estimated $74.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 30% a quarter earlier, followed by Financials and Communication Services.
Against the trend, Intermede Investment Partners opened a new position in Broadcom worth $148M.
- Intermede Investment Partners's largest Q4 2024 buy was Broadcom: 638,188 shares worth $148M.
- Intermede Investment Partners added most to Meta Platforms (Facebook) in Q4 2024, an estimated $4.71M increase.
- Intermede Investment Partners's biggest Q4 2024 reduction was Linde, cutting an estimated $83.9M.
- Intermede Investment Partners fully exited West Pharmaceutical in Q4 2024, selling an estimated $74.8M.
- Intermede Investment Partners's ten largest holdings make up 50% of its $3.75B portfolio in Q4 2024.
- Intermede Investment Partners opened 1 new position and closed 1 in Q4 2024.
- Intermede Investment Partners's portfolio value fell 22% quarter-over-quarter to $3.75B.
Based on Intermede Investment Partners's 13F filing for Q4 2024, filed 10 Feb 2025.